Sarepta could be down on patient death in FDA database, says RBC Capital
RBC Capital analyst Brian Abrahams says shares of Sarepta (SRPT) could be trading lower today on an FDA database update that ...
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
We recently published an article titled Jim Cramer’s Lightning Rounds: 9 Stocks in Focus. In this article, we are going to ...
Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Sarepta Therapeutics: Buy Rating Affirmed on Positive EMBARK Study Results and Strong Financial Outlook
Tazeen Ahmad, an analyst from Bank of America Securities, maintained the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The ...
Nisa Investment Advisors LLC Purchases 247 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Nisa Investment Advisors LLC grew its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 23.1% ...
Brokers Set Expectations for SRPT Q4 Earnings
Investment analysts at William Blair issued their Q4 2025 earnings per share (EPS) estimates for Sarepta Therapeutics in a research report issued to clients and investors on Monday, January 27th.
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...
PMLiVE5d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
ENDPOINTS NEWS6d
Sarep­ta shares two-year DMD study da­ta that could in­form Eu­ro­pean ap­proval de­ci­sion
Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene ...
Insider Monkey3d
Jim Cramer Says ‘I Think Sarepta Therapeutics, Inc. (SRPT) Is A Speculative Situation Where They Have Great Science’
In this article, we are going to take a look at where Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stands against the other stocks. Jim Cramer, the host of Mad Money, recently expressed his concerns ...